Trials (Apr 2023)

ESTIMation of the ABiLity of prophylactic central compartment neck dissection to modify outcomes in low-risk differentiated thyroid cancer: a prospective randomized trial

  • Dana Hartl,
  • Yann Godbert,
  • Xavier Carrat,
  • Stéphane Bardet,
  • Audrey Lasne-Cardon,
  • Pierre Vera,
  • Elena Ilies,
  • Slimane Zerdoud,
  • Jérôme Sarini,
  • Mohamad Zalzali,
  • Luigi La Manna,
  • Olivier Schneegans,
  • Antony Kelly,
  • Philppe Kauffmann,
  • Patrice Rodien,
  • Laurent Brunaud,
  • Solange Grunenwald,
  • Elie Housseau,
  • Salim Laghouati,
  • Nathalie Bouvet,
  • Elodie Lecerf,
  • Julien Hadoux,
  • Livia Lamartina,
  • Martin Schlumberger,
  • Isabelle Borget

DOI
https://doi.org/10.1186/s13063-023-07294-0
Journal volume & issue
Vol. 24, no. 1
pp. 1 – 22

Abstract

Read online

Abstract Background Prophylactic central neck dissection in clinically low-risk cT1bT2N0 papillary thyroid carcinoma is controversial, due to a large number of conflicting retrospective studies, some showing an advantage in terms of locoregional recurrence, others showing no advantage. These previous studies all show high rates of excellent response. We aim to demonstrate the non-inferiority of thyroidectomy alone as compared to total thyroidectomy with prophylactic central neck dissection in conjunction with adjuvant RAI 30 mCi with rTSH stimulation in terms of excellent response at 1 year. Trial design and methods Prospective randomized open multicenter phase III trial including patients with 11–40-mm papillary thyroid carcinoma (Bethesda VI) or suspicious cytology (Bethesda V) confirmed malignant on intra-operative frozen section analysis, with no suspicious lymph nodes on a specialized preoperative ultrasound examination. Patients will be randomized 1:1 into two groups: the reference group total thyroidectomy with bilateral prophylactic central neck dissection, and the comparator group total thyroidectomy alone. All patients will receive an ablative dose of 30mCi of radioactive iodine (RAI) within 4 months of surgery. The primary outcome is to compare the rate of excellent response at 1 year after surgery between the groups, as defined by an unstimulated serum thyroglobulin (Tg) level ≤ 0.2 ng/mL with no anti-Tg antibodies, an normal neck ultrasound and no ectopic uptake on the post-RAI scintiscan. Non-inferiority will be demonstrated if the rate of patients with excellent response at 1 year after randomization does not differ by more than 5%. Setting the significance level at 0.025 (one-sided) and a power of 80% requires a sample size of 598 patients (299 per group). Secondary outcomes are to compare Tg levels at 8 +/− 2 postoperative weeks, before RAI ablation, the rate of excellent response at 3 and 5 years, the rate of other responses at 1, 3, and 5 years (biochemical incomplete, indeterminate, and structurally incomplete responses), complications, quality of life, and cost-utility. Discussion (potential implications) If non-inferiority is demonstrated with this high-level evidence, prophylactic neck dissection will have been shown to not be necessary in clinically low-risk papillary thyroid carcinoma. Trial registration NCT 03570021. June 26,2018

Keywords